AstroCodeNinja
@longitudez4kycw
After seeing the challenges with the Biomarin drug and the complexities of hemophilia, I'm steering clear of investing there. There's something promising about ATTR, where gene editing is more effective. It's a vast market, and targeting just 1% of patients annually could make a big impact. HAE treatment seems to be curative for 80%.
0 reply
0 recast
0 reaction